Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: SENSORION

Market Cap 119M 136M 110M 103M 193M 12.86B 194M 1.3B 506M 6.34B 512M 501M 21.97B P/E 2026 *
-15.4x
P/E 2027 * -3.55x
Enterprise Value -13.1M -15.03M -12.08M -11.36M -21.25M -1.42B -21.4M -144M -55.8M -698M -56.43M -55.22M -2.42B EV / Sales 2026 *
-0.6x
EV / Sales 2027 * 18.6x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-1.48%-12.18%-13.39% 43.44B
+3.31%+13.04%+316.43%+562.02% 33.54B
-1.70%-7.90%+8.87%-22.34% 28.48B
+2.84%+2.48%+6.32%+34.93% 29.2B
-0.57%+3.77%+12.66%+20.42% 25.34B
-0.14%+10.03% - - 14.36B
+0.68%-1.19%+54.47%+107.47% 13.05B
+0.54%-3.88%+3.69%+2.24% 12.67B
-0.26%+1.09%+105.03%+80.69% 12.28B
Average +0.53%+0.80%+61.91%+96.51% 23.6B
Weighted average by Cap. +0.66%+0.79%+65.10%+109.05%

Financials

2026 *2027 *
Net sales 21.86M 25.09M 20.15M 18.95M 35.46M 2.36B 35.71M 240M 93.1M 1.17B 94.16M 92.15M 4.04B 6.4M 7.34M 5.9M 5.54M 10.37M 692M 10.45M 70.14M 27.24M 341M 27.55M 26.96M 1.18B
Net income -4.34M -4.98M -4M -3.76M -7.04M -469M -7.09M -47.6M -18.49M -231M -18.7M -18.3M -802M -50.64M -58.12M -46.68M -43.91M -82.15M -5.48B -82.72M -555M -216M -2.7B -218M -213M -9.36B
Net Debt -132M -151M -122M -114M -214M -14.28B -216M -1.45B -562M -7.04B -569M -556M -24.39B -
Logo SENSORION
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!